PriceTargets.com logo

Fresenius SE & Co. KGaA - FSNUY Stock Price Target and Predictions

  • Consensus Rating: Strong Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 1 Strong Buy Ratings
$8.66 As of 12/20/2024 06:55 PM ET
▼ -0.16 (-1.81%)

This chart shows the closing price for FSNUY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Fresenius SE & Co. KGaA Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FSNUY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FSNUY

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Fresenius SE & Co. KGaA in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $8.66.

This chart shows the closing price for FSNUY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Strong Buy

The current consensus among 1 polled investment analysts is to buy (strong buy) stock in Fresenius SE & Co. KGaA. This rating has held steady since August 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024
  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/25/2024CitigroupUpgradeStrong-Buy
9/5/2023HSBCDowngradeBuy ➝ Hold
8/9/2023Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy
8/1/2023CitigroupInitiated CoverageBuy
7/12/2023The Goldman Sachs GroupInitiated CoverageNeutral
1/2/2023Jefferies Financial GroupUpgradeHold ➝ Buy
12/12/2022CitigroupInitiated CoverageBuy
11/28/2022UBS GroupUpgradeNeutral ➝ Buy
10/27/2022BarclaysLower TargetOverweight ➝ Overweight€35.00 ➝ €34.00
10/26/2022Credit Suisse GroupLower Target€30.00 ➝ €24.00
10/26/2022Deutsche Bank AktiengesellschaftLower Target€28.00 ➝ €25.00
10/26/2022Berenberg BankLower TargetBuy ➝ Buy€54.95 ➝ €46.10
10/18/2022Morgan StanleyInitiated CoverageEqual Weight
8/19/2022Berenberg BankLower Target€60.25 ➝ €54.95
8/12/2022HSBCUpgradeHold ➝ Buy
7/29/2022DZ BankDowngradeBuy ➝ Hold€26.00
5/31/2022BarclaysBoost TargetOverweight ➝ Overweight€50.50 ➝ €52.50
5/13/2022JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral€34.50 ➝ €33.30
5/10/2022HSBCDowngradeBuy ➝ Hold
5/6/2022Credit Suisse GroupBoost Target€35.00 ➝ €38.00
2/28/2022Credit Suisse GroupLower TargetNeutral ➝ Neutral€43.00 ➝ €35.00
2/25/2022Deutsche Bank AktiengesellschaftLower TargetHold ➝ Hold€38.00 ➝ €36.00
2/25/2022Societe GeneraleLower TargetBuy ➝ Buy€94.00 ➝ €87.00
2/24/2022JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral€42.30 ➝ €34.50
2/16/2022Berenberg BankBoost TargetBuy ➝ Buy€55.95 ➝ €60.25
12/1/2021Deutsche Bank AktiengesellschaftReiterated RatingHold
11/23/2021HSBCInitiated CoverageBuy
11/11/2021Jefferies Financial GroupUpgradeUnderperform ➝ Hold
11/9/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral
10/26/2021Deutsche Bank AktiengesellschaftReiterated RatingHold
9/10/2021BarclaysReiterated RatingOverweight
8/11/2021JPMorgan Chase & Co.Reiterated RatingOverweight
8/4/2021Societe GeneraleReiterated RatingBuy
8/2/2021Credit Suisse GroupReiterated RatingNeutral
7/23/2021BarclaysSet TargetOverweight$13.36
7/22/2021JPMorgan Chase & Co.Reiterated RatingOverweight
7/21/2021Morgan StanleyReiterated RatingOverweight
7/21/2021Deutsche Bank AktiengesellschaftReiterated RatingHold
7/21/2021UBS GroupUpgradeNeutral
5/12/2021DZ BankReiterated RatingBuy
4/28/2021BarclaysReiterated RatingOverweight
2/19/2021Berenberg BankReiterated RatingBuy
2/10/2021JPMorgan Chase & Co.Reiterated RatingOverweight
2/4/2021Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold
2/3/2021DZ BankReiterated RatingBuy
2/2/2021BarclaysReiterated RatingOverweight
1/6/2021Nord/LBReiterated RatingBuy
12/3/2020Bank of AmericaDowngradeBuy ➝ Neutral
11/26/2020DZ BankReiterated RatingBuy
11/10/2020Deutsche Bank AktiengesellschaftReiterated RatingBuy
11/2/2020Morgan StanleyReiterated RatingOverweight
9/23/2020BarclaysUpgradeEqual Weight ➝ Overweight
8/14/2020JPMorgan Chase & Co.Reiterated RatingOverweight
8/5/2020Jefferies Financial GroupDowngradeHold ➝ Underperform
6/1/2020BarclaysReiterated RatingEqual Weight
5/20/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight
5/19/2020JPMorgan Chase & Co.Reiterated RatingOverweight
4/27/2020BarclaysReiterated RatingEqual Weight
4/23/2020JPMorgan Chase & Co.Reiterated RatingOverweight
3/24/2020Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform
(Data available from 12/22/2019 forward)

News Sentiment Rating

0.48 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/25/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/25/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/24/2024
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/23/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/23/2024
  • 2 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/22/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/22/2024

Current Sentiment

  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Fresenius SE & Co. KGaA logo
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.
Read More

Today's Range

Now: $8.66
Low: $8.49
High: $8.69

50 Day Range

MA: $8.97
Low: $8.54
High: $9.37

52 Week Range

Now: $8.66
Low: $6.57
High: $9.78

Volume

153,151 shs

Average Volume

52,521 shs

Market Capitalization

$19.35 billion

P/E Ratio

12.05

Dividend Yield

N/A

Beta

1.03

Frequently Asked Questions

What sell-side analysts currently cover shares of Fresenius SE & Co. KGaA?

The following Wall Street research analysts have issued reports on Fresenius SE & Co. KGaA in the last year: Citigroup Inc..
View the latest analyst ratings for FSNUY.

What is the current price target for Fresenius SE & Co. KGaA?

0 Wall Street analysts have set twelve-month price targets for Fresenius SE & Co. KGaA in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Fresenius SE & Co. KGaA in the next year.
View the latest price targets for FSNUY.

What is the current consensus analyst rating for Fresenius SE & Co. KGaA?

Fresenius SE & Co. KGaA currently has 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Strong Buy."
View the latest ratings for FSNUY.

What other companies compete with Fresenius SE & Co. KGaA?

Other companies that are similar to Fresenius SE & Co. KGaA include Luxottica Group, Zimmer Biomet, Solventum, Smith & Nephew and Penumbra. Learn More about companies similar to Fresenius SE & Co. KGaA.

How do I contact Fresenius SE & Co. KGaA's investor relations team?

Fresenius SE & Co. KGaA's physical mailing address is Else-Kroner-Strasse 1, Bad Homburg 2M, 61352. The company's listed phone number is (496) 172-6080 and its investor relations email address is [email protected]. The official website for Fresenius SE & Co. KGaA is www.fresenius.com. Learn More about contacing Fresenius SE & Co. KGaA investor relations.